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Colorado Health Care System, University of Colorado, Denver COA B S T R A C TBackground: Real-world patients’ medication adherence is lower
than that of clinical trial patients. Hence, the effectiveness of medi-
cations in routine practice may differ. Objectives: The study objective
was to compare the outcomes of an adherence-naive versus a
dynamic adherence modeling framework using the case of statins
for the primary prevention of cardiovascular (CV) disease. Methods:
Statin adherence was categorized into three state-transition groups
on the basis of an epidemiological cohort study. Yearly adherence
transitions were incorporated into a Markov microsimulation using
TreeAge software. Tracker variables were used to store adherence
transitions, which were used to adjust probabilities of CV events over
the patient’s lifetime. Microsimulation loops “random walks” esti-
mated the average accrued quality-adjusted life-years (QALYs) and
CV events. For each 1,000-patient microsimulations, 10,000 outer
loops were performed to reﬂect second-order uncertainty. Results:
The adherence-naive model estimated 0.14 CV events avoided per
person, whereas the dynamic adherence model estimated 0.08 CVee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.06.010
w.edu.
ndence to: Julia F. Slejko, Pharmaceutical Outcomes
30, Seattle, WA 98195.events avoided per person. Using the adherence-naive model, we
found that statin therapy resulted in 0.40 QALYs gained over the
lifetime horizon on average per person while the dynamic adherence
model estimated 0.22 incremental QALYs gained. Subgroup analysis
revealed that maintaining high adherence in year 2 resulted in
0.23 incremental QALYs gained as compared with 0.16 incre-
mental QALYs gained when adherence dropped to the lowest level.
Conclusions: A dynamic adherence Markov microsimulation model
reveals risk reduction and effectiveness that are lower than with an
adherence-naive model, and reﬂective of real-world practice. Such a
model may highlight the value of improving or maintaining good
adherence.
Keywords: comparative effectiveness research, cost-effectiveness,
decision-analytic model, medication adherence.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Evidence used in drug evaluations is often based on results from
randomized controlled trials (RCTs). It is known, however, that
RCTs have limited generalizability to real-world populations due
to their restrictive inclusion criteria [1,2]. One component of this
limitation is patients’ medication adherence. It is known that
patients’ medication adherence and persistence in the real world
is often lower than that of trial patients [3]. This is especially true
in the case of preventive medication for asymptomatic condi-
tions such as statins for hyperlipidemia treatment in the setting
of primary prevention for cardiovascular (CV) disease [4].
Decision-analytic models aiming to quantify the comparative or
cost-effectiveness of drugs rarely take into account medicationadherence and assume trial-based efﬁcacy rather than real-world
effectiveness [5]. Models typically assume a constant rate of
medication adherence and impose the risk reduction rates from
the trial onto the cohort in the simulated model. Such models are
“naive” to potential transitions in adherence over time and
related changes in drug effectiveness. This may be a limitation,
particularly in a comparison between drug products whose trial-
based efﬁcacy may be similar but to which patients’ adherence
may be differential.
The ISPOR Economics of Medication Compliance and Persis-
tence Working Group reviewed a number of methods that may be
appropriate for incorporating adherence and persistence in cost-
effectiveness analyses and cited studies that had incorporated
such methods [6]. It was concluded that the inclusion ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Research and Policy Program, University of Washington School of
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yet few studies have addressed it and therefore recommended
that further research in this ﬁeld is needed. Because decision
makers increasingly desire real-world evidence for reimbursement
decisions, research expands to address this need [7]. Methodology
for simulation models used for both cost-effectiveness analysis
and comparative effectiveness research should begin to address
real-world medication adherence because it is linked to real-world
effectiveness. Two previous statin modeling studies that have
focused on adherence have illustrated that incorporating medi-
cation adherence is able to reveal the real-world cost-effectiveness
of drugs [8,9]. There is still a need, however, for a simple and clear
illustration of a practical modeling approach to which researchers
may refer when tackling medication adherence simulation.
Two challenges exist in incorporating adherence patterns into
a decision-analytic model. The ﬁrst challenge is related to trans-
lating evidence about adherence and outcomes into model
parameter estimation. The second is related to the Markov
assumption: state transitions do not carry patients’ history to
the next state and therefore do not inﬂuence future transitions
[10]. Although this may be overcome to some degree with the
addition of states to reﬂect “postevent” consequences, the num-
ber of states needed to reﬂect this may quickly become unman-
ageable. We present a microsimulation modeling approach for
overcoming these technical and conceptual challenges using an
example of statins for the primary prevention of CV disease. Our
objective was to incorporate real-world statin adherence esti-
mates and related changes in drug effectiveness into a Markov
microsimulation model to assess statins for primary prevention.Methods
A published Markov cohort decision-analytic model was previ-
ously used to estimate the effectiveness of statin therapy as
compared with no treatment for the primary prevention of CV
events (myocardial infarction and stroke) in adults [11]. This model
assumed static, RCT-comparable adherence and did not take into
account medication adherence changes over time. We used this
existing “adherence-naive” model as a foundation for a “dynamic
adherence” model that incorporated real-world adherence tran-
sitions. The conversion of the adherence-naive model to a
dynamic adherence model required both conceptual and technical
additions to the model (Table 1). It was hypothesized that real-
world adherence, known to be suboptimal, would lead to
decreased effectiveness of statins, thereby preventing fewer CV
events and reducing quality-adjusted life-years (QALYs) gained.
Model Structure and Assumptions
In the adherence-naive model, it was assumed that patients
adhered to medications at a rate that achieved rates of efﬁcacy
observed in the RCT [12]. The model was naive to potential
transitions in adherence over time. The model construction andTable 1 – Data needs for adherence-naive and dynamic a
Model parameter Adherence-naive model
Adherence
transition
probabilities
NA—In this model, it is assumed that pati
maintain constant adherence at levels o
the trial.
Drug effectiveness Risk reduction due to statins was based on
reported efﬁcacy for cardiovascular even
interest.
NA, not applicable/available; RCT, randomized controlled trial.simulation were performed using TreeAge Pro 2013 (TreeAge
Software, Inc., Williamstown, MA).
Effectiveness, measured in QALYs, was estimated for each health
state using community-based EuroQol ﬁve-dimensional question-
naire scores [13,14], which were accrued over 1-year cycle lengths
until patients entered the absorbing state of death (CV-related or
non-CV) or reached the age of 100 years. The model structure and
parameters have been described at length in a previous publication
[11]. Several adaptations were made to the published model and are
described here. This reﬂected a primary prevention strategy for
adults with average cholesterol levels, as seen in the Justiﬁcation for
the Use of Statins in Primary Prevention: An Intervention Trial
Evaluating Rosuvastatin [12]. The baseline rates of events (trans-
formed into probabilities) and risk reduction associated with statins
are described in Table 2. After experiencing an event in the model (e.
g., nonfatal myocardial infarction or stroke), patients were assumed
to experience the average costs, QALYs, and risk of death reﬂecting
the cohort of individuals with existing CV disease in the United
States (the postevent state, Fig. 1). The postevent state was a
simpliﬁcation of the reality that patients may experience multiple
CV events, or develop heart failure. In addition, statin use was not
explicitly modeled after patients experienced a CV event. The
cohort’s QALYs were calculated for the remainder of their lifetime
on the basis of the average experience of the population that has
survived a vascular event. One thousand model microsimulation
loops “random walks” were performed to estimate the average
accrued QALYs. For each group of microsimulations, second-order
uncertainty was reﬂected by performing 10,000 outer loops. The
chosen number of random walks and loops was deemed to be
sufﬁciently large. In the outer loop, the following parameters were
drawn from distributions representing the mean value: baseline
probability of myocardial infarction and stroke, statin effectiveness,
and statin effectiveness adjustment (where applicable) (Table 2).
Subgroup analyses were performed to explore the changes in
effectiveness for patients at each of the three adherence levels in
their second year of statin use.
Conceptual Approach to Modeling Adherence
Medication adherence as a state-transition model
Statin adherence was conceptualized as “levels,” to be more easily
represented by a state-transition model. Adherence to statins
measured on a continuous scale of proportion of days covered
(PDC) was categorized into three levels similar to previous studies,
as illustrated in Figure 1: PDC Z 0.80, 0.20 r PDC o 0.80, PDC o
0.20 [15,16]. Adherence category (level) was assigned for each year,
thereby allowing transition between levels after each yearly cycle.
Once adherence was conceptualized as a categorical measure,
it was reﬂected as individual health states in a Markov state-
transition model (Fig. 1). In the adherence-naive model, the
“healthy” state represented patients who were taking statins
and had not experienced a CV event. In the dynamic adherence
model, the healthy state is illustrated as three individual healthydherence models
Dynamic adherence model
ents
bserved in
Estimates of the probability that patients will
remain adherent to medication are used to
inform transition probabilities.
RCT-
ts of
Evidence on the link between adherence
transitions and changes in drug effectiveness
are used to adjust RCT-based rates of efﬁcacy.
Table 2 – Statin effectiveness adjustments associated with adherence.*
CV event Baseline yearly
probability†
Statin effectiveness†
(risk ratio)
Adherence adjustment factor†,‡ (hazard ratio)
a b c c c
PDC o .20 .20 r PDC o .80 PDC Z
.80
Myocardial
infarction
0.0037 (β distribution
α ¼ 68, β ¼ 8833)
0.46 SE: 0.102
(β distribution)
2.714 SE: 0.367
(γ distribution)
1.16 SE: 0.146
(γ distribution)
1
Stroke 0.0034 (β distribution
α ¼ 64, β ¼ 8837)
0.52 SE: 0.115
(β distribution)
CV, cardiovascular; PDC, proportion of days covered; SE, standard error.
* CV event probabilities were calculated as follows: Statin users: a  b  c. No statin: a only.
† These parameters were varied in 10,000 outer loops of the microsimulation to represent second-order uncertainty. The distribution type for
each is described here.
‡ Ceiling limits were used such that the resulting CV risk could not be greater than the baseline risk.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 2 5 – 7 3 1 727states representing the three levels of adherence that may be
exhibited by primary prevention statin users.
Data needs for the dynamic adherence model
To convert the adherence-naive model to the dynamic adherence
model, a number of data needs were addressed with additional
model parameter estimates relating to the conceptual addition of
adherence to an existing Markov model. These data elements are
summarized in Table 1 and explained in further detail below.
Adherence transition probabilities
The typical assumption of many models is that patients maintain
trial-based adherence throughout model cycles. We modiﬁed this
assumption by modeling patients beginning statin treatment
with high adherence and modeling adherence transitions after
the ﬁrst year of treatment. These transition probabilities were
informed by a published pharmacy claims analysis (Table 3) [17].
The yearly PDC was calculated by dividing the summed statin
prescription ﬁlls by the number of days in the yearly time period.
In each period, surplus statin from overlapping reﬁlls was carried
forward and/or carried over to the following period, thereby
reducing inﬂated adherence measures due to reﬁlls at the veryHealthy
Post-
CV 
Event
Death
Categorical 
adherence levels
were added to th
Markov model a
additional health
states.
Medication adherence reconceptualized as a categorical 
measure.
Fig. 1 – Conceptual conversion of adherence-naive to dynamic a
covered.end of the yearly period [18]. Because the interest of this study
was patterns of statin exposure in primary prevention, adherence
was estimated until the point of an identiﬁed CV event, or the
end of 3 years. Transition probabilities were derived from these
yearly adherence rates.
After the ﬁrst year of statin use, individuals had a probability
of remaining highly adherent, or transitioning to a lower level of
adherence. Patients’ year 2 adherence level was predictive of
transition probabilities in year 3 and beyond. Adherence tended
to decay over time, and patients had a higher probability of
transitioning to lower levels such that few patients would remain
in the highest level over time.Drug effectiveness
Reduced medication adherence was assumed to result in reduced
effectiveness, as evidenced in previous studies [19–22]. The
magnitude of this effectiveness reduction was obtained from a
previous study by the authors that estimated the association
between changes in adherence to statins and changes in the risk
of CV events (Table 2) [17]. The estimated association between
the level of adherence and outcome was not linear and is
described in detail below. 
e 
s 
 
Level 
1
Level 
2
Level 
3
PDC = 0 PDC = 1.0PDC = 0.20 PDC = 0.80
Post-CV 
EventDeath
Healthy
Level 1
Adherence
Healthy
Level 2
Adherence
Healthy
Level 3
Adherence
dherence model. CV, cardiovascular; PDC, proportion of days
Table 3 – Adherence transition probabilities.
Year 1 adherence PDC Z.80 Transition probabilities (year 3 and beyond)
Transition probabilities (year 2) PDC o .20 .20 r PDC o .80 PDC Z .80
PDC o .20
6.08% 79.97% 11.99% 8.05%
.20 r PDC o .80
23.70% 37.22% 34.27% 28.52%
PDC Z .80
70.22% 11.31% 15.77% 72.92%
PDC, proportion of days covered.
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Technical conversion to the dynamic adherence model
The adherence-naive model was modiﬁed to a Markov micro-
simulation (“random walk”) to incorporate patients’ dynamic
adherence. The model simulated the real-world scenario that a
patient’s adherence to statin therapy was variable according to
observational data that are representative of the US census
population and resulted in different outcomes [17]. It was
assumed that individuals began statins exhibiting the highest
level of adherence (Z80%), experienced trial-based statin effec-
tiveness, and then experienced adherence transitions after the
ﬁrst cycle.
The adherence-naive model structure was modiﬁed to accom-
modate changing adherence levels (Fig. 2). This was accom-
plished by adding additional decision nodes at the end of the
cycle. Individuals in the model who remained in the healthy state
during the ﬁrst cycle faced the probability of a transition in the
adherence level at the end of the cycle, indicating the adherence
level for the next model cycle (Fig. 2). As patients moved through
the model, at the end of the year i, an initial transition probability
informed the transition to an adherence level for the next year.
Transition probabilities for subsequent cycles were selected given
the adherence level in year i (Table 2). The level of adherenceAt the en
was chos
transition
global ma
In the first y
cycles, the a
for the curre
Fig. 2 – Technical conversion of adherence-naive to dynamic adh
PDC, proportion of days covered.chosen at the end of year i was stored in a global matrix for year i
þ1 before the individual entered the next model year (i þ 1)
(Fig. 2). At the beginning of year i þ 1, a tracker variable used the
value stored in the global matrix to reﬂect the current cycle’s
adherence level. The selected level was also stored as a tracker
variable for years 2 and 3, allowing post hoc subgroup analysis.
This process continued for all model cycles in which the individ-
ual did not experience an event or death. The model was
validated internally by comparing results of the naive- and
dynamic adherence models. By using static adherence measures
in the dynamic model, results similar to the naive model were
produced.
Drug effectiveness changes
In the ﬁrst cycle, patients’ risk of CV and adverse events was
unchanged because the highest level of adherence was assumed.
In subsequent model cycles, these risks were adjusted given the
level of adherence exhibited in that cycle. Results of a claims-
based survival analysis were used to adjust the overall risk of
events [17]. This study described increase in CV event hazard for
changes in adherence after 1 and 2 years of statin use. Because of
the lifetime horizon of this model, the hazard increases associ-
ated with adherence in the third year of statin use were appliedDynamic Adherence Model
d of the model cycle, the adherence level for the next cycle 
en given the probability of remaining in the current level, or 
ing to another level. The chosen level was stored in the 
trix for the next cycle (year + 1).
Dynamic Adherence Model
ear, the default adherence level was ‘3’.  In subsequent 
dherence level in the global matrix was stored as a tracker 
nt year. Trackers for individual years were also stored.
erence model. CV, cardiovascular; MI, myocardial infarction;
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Patients using statins had a baseline probability of CV events,
which was multiplied by the trial-based rate of effectiveness (RCT
risk ratio) [17]. The hazard ratios found in the aforementioned
survival analysis (described in Table 2) then further adjusted the
probabilities to reﬂect adherence behavior. Patients exhibiting
the highest level of adherence were the reference group, such
that their risk of CV events on statins was unchanged. Ceiling
limits were used such that the resulting CV risk could not be
greater than the baseline risk. The survival model results inform
change in risk on the basis of two lags of adherence, years 2 and
3. The estimates for year 3 were used for all model cycles beyond
year 3. Adverse event probabilities were assumed to be
unchanged at all levels of adherence.Results
In the dynamic adherence model simulated cohort, 69% of the
patients exhibited highest adherence, 23% exhibited intermediate
adherence, and 6% exhibited low adherence in year 2, and 2%
experienced a CV event or died in the ﬁrst year. Using the
adherence-naive model (assumed static adherence seen in
RCT), it was estimated that statin therapy resulted in 0.40 QALYs
gained over the lifetime horizon on average per person. The
dynamic adherence model estimated that statin therapy resulted
in 0.22 incremental QALYs gained over the lifetime horizon on
average per person. In the 10,000 trials simulated using 1000
patients in the adherence-naive model, statin therapy resulted in
0.14 CV events avoided per person. Using the dynamic adherenceTable 4 – Markov microsimulation results
Overall analysis QALYs gained, mean 
SD (95% CI)
Incremen
QALYs ga
Model type
Adherence-naive
model
Statin: 13.10  0.16 (95% CI
12.78–13.41)
0.40
No statin: 12.70  0.15 (95% CI
12.40–13.00)
Dynamic
adherence
model
Statin: 12.92  0.19 (95% CI
12.55–13.29)
0.22
No statin: 12.70  0.15 (95% CI
12.40–12.99)
Subgroup analysis: Dynamic
adherence model
QALYs gained, mean
 SD (95% CI) In
QA
Adherence level in year 2*
PDC o .20 Statin: 12.86  0.19 (95%
CI 12.48–13.23)
No statin: 12.70  0.15
(95% CI 12.40–12.99)
.20 r PDC o .80 Statin: 12.91  0.19 (95%
CI 12.54–13.28)
No statin: 12.70  0.15
(95% CI 12.40–12.99)
PDC Z .80 (reference) Statin: 12.93  0.19 (95%
CI 12.57–13.30)
No statin: 12.70  0.15
(95% CI 12.40–12.99)
CI, conﬁdence interval; CV, cardiovascular; PDC, proportion of days cove
* After year 2, patients’ continued transitioning through adherence levelmodel, statin therapy resulted in 0.08 CV events avoided per
person (Table 4). The difference in CV events by treatment group
was statistically signiﬁcant in both models. Subgroup analysis
revealed that maintaining high adherence in year 2, followed by
adherence transitions in subsequent years, resulted in 0.23
incremental QALYs gained and 0.08 events avoided as compared
with 0.16 incremental QALYs gained and 0.07 events avoided
when adherence dropped to the lowest level in year 2, followed
by adherence transitions in subsequent years.Discussion
This study provides a contribution to the modeling and compa-
rative effectiveness literature by presenting a technical and
conceptual framework for incorporating medication adherence
into a Markov model. Although incorporating history into a
Markov model is often unwieldy, recent work has shown its
importance [23] and we have illustrated a straightforward
approach for modeling adherence history. This work may serve
as a practical guide for researchers wishing to build comparative
effectiveness research models that incorporate real-world med-
ication adherence evidence. Although the data needs for a
dynamic adherence model may be viewed in the realm of
parameter uncertainty, the choice to incorporate real-world
adherence may be seen as an element of structural uncertainty.
One may conceptualize dynamic adherence as a shift from one
representative “healthy” state to several, as we have here.
Because new ISPOR modeling guidelines have recently emerged
[24], this approach may be considered by researchers wishing total
ined
CV events, mean  SD CV events avoided
with statin
Statin: 0.18  0.03 (95% CI
0.12–0.23)
0.14
No statin: 0.32  0.03 (95%
CI 0.27–0.37)
Statin: 0.24  0.03 (95% CI
0.18–0.29)
0.08
No statin: 0.32  0.03 (95%
CI 0.27–0.37)
cremental
LYs gained
CV events, mean 
SD
CV events
avoided with
statin
0.16 Statin: 0.25  0.03 (95%
CI 0.20–0.31)
0.07
No statin: 0.32  0.03
(95% CI 0.27–0.37)
0.21 Statin: 0.24  0.03 (95%
CI 0.19–0.30)
0.08
No statin: 0.32  0.03
(95% CI 0.27–0.37)
0.23 Statin: 0.24  0.03 (95%
CI 0.18–0.29)
0.08
No statin: 0.32  0.03
(95% CI 0.27–0.37)
red; QALY, quality-adjusted life-year.
s using the aforementioned transition matrix in Table 2.
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modeling approach also provides a technical advantage over
average patient cohort models by permitting simple subgroup
analyses. The dynamic adherence model showed an overall
difference in the QALYs gained and events avoided by subgroup.
The Markov microsimulation approach allows the illustration of
value differences by subgroup, an advantage over average patient
cohorts. By examining the subgroup analysis results, we found
that for those in the lowest level of adherence in year 2, although
the least likely scenario, QALYs gained decrease and CV events
increase than for those who remain at the highest level of
adherence.
This study provides a platform for the comparison of drugs
with differential adherence and a means to estimate the value of
adherence-improving interventions. Although our example
examined statin treatment versus no statin, this is simply an
example to illustrate the approach. Statins are widely considered
to be valuable and effective without question. This type of
analysis, however, could be very useful in a case in which the
relative effectiveness of a new drug is in question, and may have
an advantage of better patient adherence. A model may use two
active drug arms in which the adherence probability transition
matrices vary (Table 3). Although good adherence to either drug
may result in good clinical effectiveness, a priori evidence about
patients’ adherence may inform such a model and will provide
both overall effectiveness results and subgroup results for low
versus high adherers, such as in Table 4. This approach may be
particularly useful to assess, for example, the new class of oral
anticoagulants, in which adherence among the various agents
may differ, and be compared to traditional strategies that incor-
porate closer patient monitoring. Recent literature has suggested
that adherence be considered when selecting the appropriate
anticoagulant for patients [25]. It will also be important to
consider the value and effectiveness of agents given potential
adherence [26]. In this case, a method for simulating patients’
adherence will be valuable. This methodology may also be
applied to a scenario in which severe adverse effects or undesir-
able dosing regimens greatly affect adherence and an alternative
exists that does not pose such problems. Health care payers in
the United States may be interested in such a methodology for
these reasons.
A natural extension of this work is a cost-effectiveness model
that incorporates medication adherence. Researchers may com-
bine our approach of dynamic adherence modeling with recent
research on modifying trial-based economic analyses to be
reﬂective of clinical practice [27]. In the framework of a cost-
effectiveness analysis, a subgroup analysis similar to ours in
Table 4 may be used to interpret the value of an intervention that
would help patients maintain high adherence [28,29]. This sce-
nario may highlight the value of improving adherence, given the
cost of doing so. This may be of particular interest in valuing the
costs associated with interventions that improve adherence, a
cited research priority [30,31]. From a payer perspective, such
results may inform whether an intervention that ameliorates
medication adherence is valuable to implement, given the life-
time costs associated with CV events, for example.
Our results may be compared with those of other studies that
have modeled medication adherence [8,9]. Cherry et al. [8], in
their study of adherence to antihypertensive drugs and statins,
found that both real-world and trial-based adherence resulted in
cost-effective strategies, but adherence similar to a trial was
more cost-effective. Real-world adherence to both drugs resulted
in an incremental cost-effectiveness ratio greater than the
incremental cost-effectiveness ratio resulting from ideal adher-
ence, such as that found in a trial. Their overall conclusion is
similar to what is found in this study, despite their focus on cost-
effectiveness. Mason et al. [9] incorporated statin adherence intoa study to explore the optimal time to begin statin therapy in
those with diabetes. They also found that as adherence increases
to approach that seen in an RCT, statin therapy is more costly but
more effective than low or intermediate adherence.
A number of limitations should be considered with the results
of this study. The major assumption of our example is that of the
effect of adherence transitions on outcomes. This may vary
greatly by drug class or patient cohort, so it is important that
researchers inform their dynamic adherence model parameters
with appropriate evidence. Our input parameters for both adher-
ence transitions and CV outcomes were derived from one sample
of new statin users. Other studies have estimated some of these
parameters, but none has estimated all parameters in the same
cohort [16]. We chose to derive these using pharmacy claims, but
researchers may consider evidence from RCTs or observational
studies, while considering trade-offs typically associated with the
hierarchy of research designs [32,33]. Such evidence could be
used to validate a simulation model as well. Extensive model
validation was not performed in this case. Future work should
focus on validating simulated CV outcomes using real-world
data. A typical assumption of models is that patients remain
fully adherent to their medication for the duration of therapy. In
this model, we modiﬁed that assumption and assumed that they
were fully adherent the ﬁrst year, but exhibit adherence tran-
sitions in subsequent years. Future studies may modify this
assumption and attempt to characterize adherence in the ﬁrst
year. Given the nature of the parameter data available, it was
desirable to focus on a homogeneous population for the survival
analysis, but this should be further explored in future studies.Conclusions
This study provides a novel approach for incorporating medica-
tion adherence into a model that may be used to assess the value
of improving adherence or comparing outcomes among thera-
peutics with differential adherence. This study has two implica-
tions. First, we present an approach for modeling medication
adherence: a methodological advancement that has been
attempted by few thus far. Although this application of this
modeling methodology is presented in a comparative effective-
ness framework here, its applications may extend to cost-
effectiveness analysis as well. Second, the post hoc analysis of
such a model allows differences in effectiveness to be illustrated
among adherence subgroups. In the interest of patient-centered
research and personalized medicine, an approach that elucidates
differences in patient subgroups increases the information
gained over methods that use average patient cohorts.
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